Clinical Trials Browser

Central Nervous System Neoplasms × durvalumab × CNS × Clear all

NCT04521686 2025-06-27

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT02793466 2023-09-22

Durvalumab in Pediatric and Adolescent Patients

Phase 1 Completed

15 enrolled

CNSLymphoid

Lymphoma, Central Nervous System Neoplasms